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the World Health organization recently listed snakebite envenoming as a neglected tropical Disease, 
proposing strategies to significantly reduce the global burden of this complex pathology by 2030. In 
this context, effective adjuvant treatments to complement conventional antivenom therapy based on 
inhibitory molecules for specific venom toxins have gained renewed interest. Varespladib (LY315920) 
is a synthetic molecule clinically tested to block inflammatory cascades of several diseases associated 
with elevated levels of secreted phospholipase A2 (spLA2). Most recently, Varespladib was tested 
against several whole snake venoms and isolated pLA2 toxins, demonstrating potent inhibitory activity. 
Herein, we describe the first structural and functional study of the complex between Varespladib and 
a pLA2-like snake venom toxin (MjTX-II). In vitro and in vivo experiments showed this compound’s 
capacity to inhibit the cytotoxic and myotoxic effects of MjTX-II from the medically important South 
American snake, Bothrops moojeni. crystallographic and bioinformatics analyses revealed interactions 
of Varespladib with two specific regions of the toxin, suggesting inhibition occurs by physical blockage 
of its allosteric activation, preventing the alignment of its functional sites and, consequently, impairing 
its ability to disrupt membranes. furthermore, based on the analysis of several crystallographic 
structures, a distinction between toxin activators and inhibitors is proposed.
Venomous snakes of medical importance are widely distributed in tropical and sub-tropical countries from 
Africa, Asia, Latin-America and Oceania, being responsible for an estimated 420,000 to 1,800,000 envenomings 
every year1,2. The most affected victims are usually agricultural workers from rural areas, hunters and children 
who do not have adequate protective clothing, secure housing or education about other protective measures that 
can help prevent snakebites3. In 2017, the World Health Organization (WHO) added snakebite envenoming to its 
list of neglected tropical diseases, with a focus on strategies to reduce the burden and control the effects of these 
envenomings4,5. Further, toxin-specific treatments that could be administered at the time of a bite, or where con-
ventional serum therapies are not adequately effective, remain elusive6.
In Latin America, Bothrops species are responsible for the majority of snakebite envenomings, followed by 
Crotalus species7–9. Accidents involving the former are characterized by drastic local effects, often due to the 
action of myotoxic proteins causing muscle necrosis and, in severe cases, tissue loss, or even limb amputation and 
disability of the victim10–12.
Venoms from Bothrops snakes are composed of a set of proteins that have diversified functions13–15. Among 
venom components, several variants of secreted phospholipases A2 (PLA2s) are common in these venoms. 
Asp49-PLA2s display catalytic activity, and the basic variants are typically myotoxic, in contrast to their acidic 
counterparts which generally lack myotoxic activity. On the other hand, the Lys49-PLA2-like proteins lack cata-
lytic activity, but induce myotoxicity. By acting in synergy between themselves16 and with proteinases17, myotoxic 
Asp49-PLA2s and Lys49-PLA2-like proteins are the main venom components responsible for local myonecrosis 
in Bothrops envenomings. Asp49-PLA2 toxins are calcium-dependent small proteins (~13 kDa) with secondary 
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structure composed by three α-helices, one anti-parallel β-sheet and a calcium binding loop18,19. Their myotoxic 
activity depends on the hydrolysis of membrane phospholipids, as chemical modification of the catalytic His48 
abolishes both catalysis and myotoxicity16. On the other hand, Lys49-PLA2-like myotoxins share the same general 
scaffold as Asp49-PLA2s, but display myotoxicity in the absence of catalysis. A hypothesis on the mechanism 
of myotoxicity induced by Lys49-PLA2-like toxins was recently presented, and involves several steps. It is pro-
posed that initiation occurs by the binding of a fatty acid into the hydrophobic channel of the toxin, followed by 
allosteric activation and alignment of functional sites. These functional sites interact with the cell membrane via 
a membrane docking site (MDoS), and by the disruption of membrane integrity by the action of a membrane 
disrupting site (MDiS), ultimately resulting in cell necrosis20–22.
The cornerstone for the treatment of snakebite envenomings is antivenom administration, but scarce availa-
bility and considerable costs frequently limit the access to these life-saving antidotes in many impoverished rural 
areas of the world12. Moreover, since antivenoms have to be administered in health facilities, there is often a delay 
in antivenom infusion owing to the usual difficulties of patients to reach these facilities in many rural settings. 
In search of alternative and effective adjuvant treatments to complement the conventional antivenom therapy, 
in vitro and in vivo studies have tested a number of inhibitors against diverse crude venoms, or isolated toxins 
such as PLA2s23–32, monoclonal antibodies33–36 and synthetic molecules37–48. Ideally, these novel antidotes could 
be used in the field rapidly after the onset of envenoming, hence halting the deleterious action of venom toxins 
in the tissues. In order to understand how these inhibitors block the action of toxins, protein crystallography has 
been employed as a powerful tool to understand the inhibitory mechanisms of a variety of small ligands toward 
PLA2 toxins6,21,41,44,45,47,49,50.
Among a wide variety of molecules capable of inhibiting PLA2 enzymes51,52, one potent inhibitor of human 
secreted group IIA PLA2s is Varespladib (LY315920)53. This synthetic molecule was developed and clinically 
tested for the purpose of blocking inflammatory cascades of several diseases associated with elevated sPLA2 levels 
such as rheumatoid arthritis, sepsis and acute coronary syndrome54. Partly on the basis of homology between the 
human group IIA PLA2 and PLA2 toxins found in snake venoms, Varespladib was tested against a large panel of 
whole venoms from medically important snakes from different continents and potent inhibition of their PLA2 
activity was found42. Inhibition has been also studied using several isolated PLA2 toxins, including a myotoxin 
isolated from the venom of Bothrops asper48.
In this communication, we describe the crystal structure of MjTX-II, a PLA2-like toxin isolated from 
Bothrops moojeni55,56 co-crystallized with Varespladib, revealing two inhibitor molecules interacting with the 
hydrophobic channel of the dimeric assembly of this toxin, and a comprehensive analysis of other crystal struc-
tures of bothropic PLA2-like toxins/inhibitor complexes using bioinformatics approaches. Furthermore, we per-
formed in vitro and in vivo studies to assess the inhibition of toxic effects of MjTX-II by Varespladib. Taken 
together, the data presented hereby provide a molecular basis to understand such inhibition. This comparative 
analysis of crystallographic structures of PLA2-like toxins/inhibitors contributes to organize and classify the dif-
ferent inhibition models for toxic effects of PLA2-like toxins by different molecules into three main classes.
Results
Varespladib inhibits the in vivo myotoxicity and in vitro cytotoxicity of MjTX-II. As typical of 
Lys49 PLA2-like toxins, the intramuscular injection of 50 µg of MjTX-II in mice caused a prominent elevation 
of plasma creatine kinase activity, indicative of skeletal muscle necrosis (Fig. 1A). This increment was reduced 
by nearly 50% when the toxin was preincubated with Varespladib, a statistically significant (p < 0.05) difference. 
Preincubation with Varespladib was also able to significantly inhibit the cytotoxic action of MjTX-II on C2C12 
myoblasts in vitro, reducing the release of lactate dehydrogenase to the medium by nearly 75% in comparison to 
the effect of toxin alone (Fig. 1B).
Crystallographic structure of MjTX-II/Varespladib. MjTX-II/Varespladib crystallographic structure 
has similar folding compared to group II PLA2s proteins previously solved, showing a dimeric configuration with 
seven disulfide bridges in each protomer18,19.
MjTX-II/Varespladib crystals belong to P21 space group and diffracted up to 1.75 Å resolution. Refined data 
converge to an Rcryst of 22.42% (Rfree = 23.73%) with a dimeric final model composed of two Varespladib mole-
cules, two DMSO molecules and 93 solvent molecules (Fig. 2). Due to the lack of electron density, atoms from 
side chains of following residues are not modeled in chain A: Lys7, Lys16, Lys53, Lys69, Lys78, Lys80, Lys116, 
Lys128, and in chain B: Lys7, Lys36, Lys53, Lys69, Lys70, Lys78, Lys128 and Lys129.
Refinement statistics information for complex crystal structure is described in Table 1. The final model of the 
complex MjTX-II/Varespladib was deposited in RCSB PDB data bank, under the code 6PWH.
Molecular dynamics simulations. The MjTX-II/Varespladib complex presented a high stability as shown 
by MD simulations, evidenced by the RMSD calculations of MjTX-II backbone and Varespladib non-hydrogen 
atoms which present average values of 1.94 ± 0.27 Å and 1.76 ± 0.18 Å, respectively (Fig. 3A). In agreement with 
this, RMSF calculations of the backbone atoms of MjTX-II showed values below 5 Å (Fig. 3B).
Table 2 shows the prevalence of contacts of the toxin’s residues with Varespladib molecules below 4.5 Å. The 
majority of the residues presented interactions above 80% of the time simulation, except residues Gly32 and Tyr52 
from both monomers that interacted between 50% and 80% of the time simulation. Furthermore, Tyr121 residue 
of both monomers and Leu122 of monomer B presented the lowest values, interacting with Varespladib less than 
20% of the time simulation.
It is interesting to note that Varespladib molecules interacted with residues considered important for the 
myotoxic activity of this class of proteins, including Helix-I, MDiS, and the hydrophobic channel. The Helix-I 
residues Leu2 and Leu5 from both monomers were in contact with Varespladib molecules during the entire 
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simulation time, while the Phe126 residue of both monomers interacted almost 100% of the time. Furthermore, 
Varespladib molecules showed a maximum percentage interaction with the His48 residues from both monomers 
of the MjTX-II. The binding of Varespladib to MjTX-II partially buried its MDiS region, as shown by the compar-
ison between SASA (solvent-accessible surface area) values of MjTX-II/fatty acid (MjTX-II/myristic acid, PDB id 
6B80) (1040.76 Å2) and MjTX-II/Varespladib (834.56 Å2) structures. In addition, the stability of the complex was 
also evidenced by the favorable ΔG of −44.98 ± 7.17 kcal/mol predicted by MM-PBSA calculation.
Discussion
inhibition of pLA2-like toxins by varespladib. Varespladib has been reported to inhibit the enzymatic 
and toxic actions of a variety of snake venom PLA2s42,57, including a number of enzymes that display myotoxic 
activity48. Varespladib was able to reduce muscle damage when preincubated with the myotoxic enzymes before 
injection, as well as when the drug was administered soon after enzyme injection48. However, no information 
was available until now on the possible inhibition of catalytically-inactive PLA2-like myotoxins by this synthetic 
compound. In the present study, functional assays performed in mice and in cell culture demonstrated that 
Varespladib interacts with MjTX-II leading to a significant inhibition of its myotoxic and cytotoxic effects. In 
the absence of catalytic activity by MjTX-II, this finding suggests that Varespladib is able to interfere with the 
interaction of MjTX-II with the membrane or that it reduces its ability to disrupt plasma membrane integrity in 
muscle cells.
Varespladib appeared to be more effective in neutralizing the cytotoxic effect in vitro (75%) than the myo-
toxic action in vivo (50%), at the same inhibitor concentration (400 µM, selected from previous studies on the 
inhibition of catalytically-active PLA2s)48. It is likely that MjTX-II has a higher affinity for its target on mature 
muscle cells, compared to the myoblast cell line in culture, since an increase in susceptibility to the action of 
Lys49-PLA2-like myotoxins has been previously demonstrated to occur during the differentiation of the C2C12 
myogenic cell line58. Therefore, differences in the affinity of MjTX-II to membrane sites in mature muscle cells in 
vivo and myoblasts in vitro may explain the inhibition results obtained. Our observations for inhibition of myo-
toxicity by Varespladib led us to focus on elucidating the molecular basis of this neutralizing interaction by using 
co-crystallization and MD simulation approaches, which are valuable tools to explore the mechanisms of toxicity 
by PLA2-like proteins, and to unravel the diverse modes of inhibition exerted by different small compounds. In 
the light of the high abundance in many viperid snake venoms of PLA2-like toxins devoid of enzymatic activity, 
but capable of inducing myonecrosis, our findings underscore that Varespladib is not only effective in the inhi-
bition of catalytically-active toxic PLA2s, but also of these PLA2-like proteins, hence expanding the potential 
therapeutic usefulness of this inhibitor.
Structural evidences for inhibition of pLA2-like toxins by varespladib. A mechanism to explain 
the myotoxic activity of Lys49 PLA2-like toxins was proposed recently. This model underscores the importance of 
interaction of fatty acid molecules in the hydrophobic channel for the initial steps of the mechanism. Essentially, 
after fatty acids location into the hydrophobic channel, the monomers are reoriented, resulting in toxin activation 
Figure 1. Myotoxic and cytotoxic activities of MjTX-II in mice and cultured C2C12 myoblasts, respectively, and 
their inhibition by preincubation with Varespladib. (A) Mice were injected by intramuscular route with toxin 
alone (50 μg, in 100 μL of PBS), or preincubated for 15 min with Varespladib (VAR) at a final concentration 
of 400 μM. Control groups were injected with PBS alone or Varespladib alone, respectively. After 3 hr, blood 
was obtained and the plasma creatine kinase (CK) activity was determined, as described in Methods. Each bar 
represents the mean ± SD of 4–5 mice per group. (B) Cells were exposed to the toxin alone (20 μg, in 150 μL 
of medium), or preincubated for 15 min with Varespladib (VAR) at a final concentration of 400 μM. After 
incubating the cells for 3 hr at 37 °C, an aliquot of supernatant was assayed for lactate dehydrogenase (LDH) 
activity, as described in Methods. Cytotoxicity is expressed as percentage, considering the LDH activity of 
cells exposed to medium with 0.1% Triton X-100, or to medium alone, as 100% and 0%, respectively. Each 
bar represents the mean ± SD of three replicates. Statistically significant (p < 0.05) differences between values 
obtained with the toxin alone or the toxin preincubated with Varespladib are indicated by an asterisk.
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and, subsequently, the toxin docks and disrupts the integrity of the plasma membrane20,21,59. In this type of toxin, 
membrane disruption is completely independent of phospholipids enzymatic hydrolysis.
The crystal structure of the complex MjTX-II/Varespladib reveals the presence of inhibitor molecules in the 
hydrophobic channel of the toxin (Fig. 4), interacting particularly with His48 and Lys49 residues. The structural 
importance of these residues was also observed by MD simulation, in which they were found to interact with the 
ligand during almost the whole time (Table 2). Therefore, binding of Varespladib into the toxin’s hydrophobic 
channel is likely to prevent the membrane’s fatty acids binding and, consequently, precludes the structural align-
ment of the functional MDoS and MDiS regions, resulting in reduction of toxicity. Another structural feature 
observed was the particular dimeric assembly of MjTX-II/Varespladib when compared to other PLA2-like toxins. 
The superposition between dimeric proteins reveals a high distortion in their dimeric assembly, expressed by the 
high value of the Euler roll angle21 and RMSD values (Table 3). When compared to other PLA2-like toxins, the 
distorted conformation observed in the crystal structure of MjTX-II/Varespladib is also observed in the crystal 
structure of MjTX-II/rosmarinic acid (MjTXII/RA) and MjTX-II/acetylsalicylic acid (MjTX-II/ASA)50, suggest-
ing that this structural conformation may be related to the inactive structure of MjTX-II and also shedding light 
on how the inhibitors can influence the structure of the toxin.
Previously, MD simulations using the complexes MjTX-II/RA and MjTX-II/ASA showed that the distorted 
quaternary structural conformation of MjTX-II has some structural aspects that might be related to the myotoxic 
activity. The inhibitor RA remained bound to MjTX-II MDiS after 100 ns of MD simulation, preventing the access 
of fatty acids to the hydrophobic channel. In contrast, the ASA molecules showed an unstable interaction with 
MjTX-II, and left the hydrophobic channel of the toxin rapidly, allowing the further interaction of fatty acids 
molecules to the binding site50. In the present work, MD simulation of the MjTX-II/Varespladib complex showed 
high stability (Fig. 3A) and affinity of the inhibitor in the binding site on hydrophobic channel (Table 2), which 
suggests that Varespladib prevents the interaction of fatty acids with the toxin by competitive inhibition, and also 
preserves the distorted structure of the toxin.
The comparison of ΔG values obtained by MD simulations for MjTX-II/Varespladib and other two MjTX-II/
inhibitors complexes from the three different classes (RA and suramin inhibitors - Table 3) also revealed inter-
esting results. Although ΔG values for Varespladib and RA are in the same order of magnitude (−17.16 ± 11.67 
and −44.98 ± 7.17 kcal/mol, respectively for RA e Veraspladib), the lower value for Varespladib is according to 
structural environment of both inhibitors. RA is partially exposed to solvent and binds superficially to MjTX-II 
Figure 2. Crystal structure of the complex MjTX-II/Varespladib. (A) The overall structure of the complex is 
depicted as cartoon representation (cyan) and the inhibitor molecules are represented as sticks (yellow). (B) Omit 
electron density map (coefficients 2|Fobs| − |Fcalc|) corresponding to Varespladib bound to monomer A and (C) 
Varespladib bound to monomer B. The maps corresponding to inhibitor molecules are contoured at 1.0 σ.
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Space Group P21
Unit Cell (Å, °) a = 54.9; b = 37.2; c = 68.7; β = 114.4
Resolution range (Å) 31.28 – 1.75 (1.81–1.75)
Unique reflections 25503 (2439)
Multiplicity 4.4 (3.8)
Completeness (%) 99.7 (98.7)
Mean I/σ (I) 16.5 (2.97)
Molecules in ASU 2
Matthews coefficient VM (Å3Da−1) 2.30
Rmergea (%) 7.1 (42.2)
Reflections used in refinement 25476 (2431)
Reflections used for Rfree 1253 (116)
Rwork 21.22 (29.06)
Rfree 23.25 (27.76)
Number of non-hydrogen atoms
Protein 1887
    Water 93
    Ligands 64
Varespladib/CC 2/0.92
Average B-factor
    Overall 57.04
    Macromolecules 57.58
    Ligands 48.75
    Solvent 51.83
Ramachandran Plot (%)b
    Favored 94.17
    Allowed 5.0
    Outliers 0.83
Rotamer outliers (%) 0
Cβ outliers 0
Clashscore 6.44
RMS (bonds) (Å) 0.004
RMS (angles) (°) 1.00
Table 1. X-ray data collection and refinement statistics for MjTX-II/Varespladib structure. Numbers in 
parenthesis are for the highest resolution shell. aRmerge = Σhkl[Σi(Ihkl,i − <Ihkl> |)]/Σhkl, <Ihkl> , where Ihkl,i is the 
intensity of an individual measurement of the reflection with Miller indices h, k and l, and <Ihkl> s the mean 
intensity of that reflection. Calculated for I > −3σ (I). bCalculated with MolProbity program.
Figure 3. Molecular dynamic simulation of the MjTX-II/Varespladib complex. (A) RMSD for MjTX-II 
backbone atoms (black line) and Varespladib non-hydrogen atoms (red line). (B) Backbone atoms RMSF for 
MjTX-II chains A (dark blue line) and B (cyan line).
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while Varespladib binds into the hydrophobic channel of the toxin, indicating that Varespladib is an efficient inhib-
itor candidate for PLA2s-like toxins. Indeed, the very low ΔG value of MjTX-II/Suramin complex (−148.16 +/− 
14.64 kcal/mol) reflects the large number of interactions and between the highly charged inhibitor and the MjTX-II.
The crystallographic structure and MD simulations analyses show that Varespladib interacts with the same 
site as fatty acids. Thus, the question emerges on how these molecules can bind to this site and induce contrasting 
effects on MjTX-II? The answer may be associated with the length of the bound molecule. Fatty acids are long 
Varespladib 1 Varespladib 2
Residue Percentage (%) Residue Percentage (%)
Leu2A 100 Leu2B 100
Leu5A 100 Leu5B 100
Gly6A 99.99 Gly6B 100
Ile9A 100 Ile9B 100
Pro18A 99.88 Pro18B 99.98
Ala19A 99.98 Ala19B 100
Tyr22A 100 Tyr22B 100
Gly23A 100 Gly23B 100
Asn28A 99.94 Asn28B 99.94
Cys29A 100 Cys29B 100
Gly30A 100 Gly30B 100
Val31A 99.23 Val31B 99.95
Gly32A 78.16 Gly32B 51.22
Cys45A 100 Cys45B 100
His48A 100 His48B 100
Lys49A 99.60 Lys49B 99.65
Tyr52A 63.17 Tyr52B 60.47
Val102A 99.16 Val102B 99.40
Leu106A 100 Ley106B 99.99
Tyr121B 14.79 Tyr121A 9.35
Pro125B 100 Pro125A 100
Phe126B 97.19 Phe126A 99.85
Table 2. Prevalence of contacts, expressed as percentage, of the MjTX-II residues from monomers A and B 
forVarespladibbelow 4.5 Å along the MD simulations.
Figure 4. Schematic representation of the interaction of Varespladib molecules with MjTX-II. (A) Interaction 
of Varespladib with monomer A. (B) Contacts of Varespladib with monomer B. The figure was made using Lidia 
extension from Coot v.0.8.967.
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chain molecules, where their tails can interact with residues from Helix-I (residues from 1 to 10) and residues 
from MDiS (Leu122 and Phe126 residues), hence filling the entire hydrophobic channel, and collaborating with 
the alignment and exposure of this functional site to the solvent (Fig. 5). On the other hand, Varespladib main-
tains strong interactions with the same regions (Helix-I: Leu2, Leu5, Gly6 and Ile9 residues; MDiS: Leu122 and 
Phe126 residues; and residues His48 and Lys49), as observed in the crystal structure (Fig. 2) and MD simulations 
(Table 2), occupying the hydrophobic channel internally (Fig. 5). The interaction of Varespladib with residues of 
the hydrophobic channel forces MDiS to remain in contact with the toxin, favoring the distorted conformation. 
Indeed, SASA of the MDiS region of the MjTX-II/Varespladib is about 20% lower compared to the MjTX-II/
myristic acid structure (PDB id 6B80). Therefore, Varespladib may inhibit the myotoxin by two different mecha-
nisms: (i) hydrophobic channel blockage and (ii) preventing the MDiS exposure to the solvent.
PDB id Toxin
RMSD 
(Å)§
Roll 
Angle (°)
MDoS 
distance (Å)
MDiS distance 
A (Å)
MDiS 
distance B (Å) Binding sites
Inhibitor 
class
Toxin + Inhibitor
3HZW BthTX-IBPB 4.13 170 13.9 9.7 6.2
Hydrophobic channel in 
monomer A and B 1
2OK9 PrTX-IBPB 5.03 181 15.5 4.5 5.3
Hydrophobic channel in 
monomer A and B 1
1Y4L BaspTX-IISuramin 4.67 174 14.1 4.6 4.8
Hydrophobic channel in 
monomer A and B 1
6PWH MjTX-IIVarespladib - 163 21.1 4.8 4.5
Hydrophobic channel in 
monomer A and B andMDiS 
from both monomers
1, 2
3QNL PrTX-IRosmarinic Acid 4.54 173 14.5 4.8 5.2
Hydrophobic channel entrance 
and MDiS from monomer B 1, 2
4WTB BthTX-IZinc 4.22 142 16.8 10.3 4.7
Hydrophobic channel and 
MDiS from both monomers 1, 2
6DIK BthTX-IChicoric Acid 4.69 180 15.4 5.0 5.1
Hydrophobic channel entrance 
and MDiS from monomer B 1, 2
4YU7 PrTX-ICaffeic Acid 5.00 177 14.9 5.0 4.7 MDoS 2
4YZ7 PrTX-IAristolochic Acid 4.98 181 14.8 4.7 4.8 MDiS from monomer A 2
6MQD MjTX-IIRosmarinic Acid 0.40 166 19.3 4.7 4.8 MDiS from monomer B 2
6CE2 MjTX-ISuramin 4.99 175 14.8 8.6 9.4
Hydrophobic channel in 
monomer A and B 3
4YV5 MjTX-IISuramin 4.69 170 14.4 5.0 4.9
MDoS and MDiS 
simultaneously in both 
monomers
3
Toxin + Activator
3IQ3 BthTX-IPEG4000 5.13 178 14.5 4.7 5.2 Hydrophobic channel —
6B84 MjTX-II 3.73 164 13.7 4.4 4.5 Hydrophobic channel —
6B83 MjTX-IIFatty Acid 6 4.39 169 14.4 6.4 5.2 Hydrophobic channel —
6B81 MjTX-IIFatty Acid 8 3.77 167 13.7 4.9 5.0 Hydrophobic channel —
6B80 MjTX-IIFatty Acid 14 4.73 170 14.3 4.8 5.0 Hydrophobic channel —
1XXS MjTX-IIFatty Acid 18 4.66 170 14.8 4.4 4.7 Hydrophobic channel —
4KF3 MjTX-IIPEG4000 4.80 170 14.2 4.4 4.4 Hydrophobic channel —
3MLM BnIVFatty Acid 14 4.97 179 14.7 4.6 5.4 Hydrophobic channel —
4K06 MTX-IIPEG4000 4.99 178 14.8 5.1 4.9 Hydrophobic channel —
Inactive Toxin
2H8I BthTX-IPEG400* 4.15 141 17.0 8.5 4.9 Hydrophobic channel —
3I3H BthTX-I 4.15 141 17.5 9.3 4.6 — —
3HZD BthTX-I 4.17 141 17.3 11.2 4.8 — —
2Q2J PrTX-I 4.13 141 17.4 10.9 4.9 — —
4K09 BbTX-II 4.17 142 17.4 10.8 4.5 — —
6MQF MjTX-IIAspirin# 0.44 165 21.4 4.8 4.8
Hydrophobic channel in 
monomer A and B —
Table 3. Analysis of functional and binding sites of ligands for PLA2-like toxins from Bothrops snakes. §RMSD 
calculated using MjTX-II/Varespladib as reference structure for superposition. *Length of PEG400 molecule 
is not able to activate the toxin. #Aspirin molecules bind to toxin but do not inhibit the myotoxic effects of 
MjTX-II.
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pLA2-like toxins inhibitors. The activation of PLA2-like toxins involves important structural changes in 
their oligomeric structures with particular features after the binding of fatty acids into the solvent-exposed hydro-
phobic channel: (i) alignment of the membrane docking site (MDoS), where the distance between positive clus-
ters that comprise the MDoS (Lys16, Lys20, Lys115 and Arg118) from both monomers must be ≤16 Å; (ii) Euler 
Roll angle >160° and; (iii) changing the distance of the MDiS hydrophobic residues Leu121 (122 for MjTX-II) 
and Phe125 ≤ 5 Å21,60. These structural features were observed in recent studies by analyses of several crystal-
lographic structures of PLA2-like toxins in native form and bound with inhibitory molecules6,25,37,41,44–46,49,50,61.
Crystallographic structures of PLA2-like toxins isolated from Bothrops snake venoms in complex with dif-
ferent inhibitory ligands showed that these inhibitors may interact with the toxin in distinct regions (Table 3). 
Basically, three regions were identified, which coincidentally are involved in the myotoxic effects according to 
the structural studies: hydrophobic channel, MDoS, and MDiS regions20,21,37,45. To date, eight different inhibi-
tors have been studied in complex with different bothropic PLA2-like toxins. Their binding region(s) are next 
described: (a) bound into the hydrophobic channel (bound to His48): p-bromophenacyl bromide (BPB)41,61, Zinc 
ions37, Suramin44 and Varespladib (present work); (b) bound in the entrance of hydrophobic channel: Chicoric 
acid25 and Rosmarinic acid49; (c) bound to the membrane disrupting site (MDiS): Zinc ions37, Aristolochic acid6, 
Chicoric acid25 and Rosmarinic acid50; (d) bound with MDoS residues: Caffeic acid6; (e) bound simultaneously to 
MDoS and MDiS regions and also induces protein oligomerization: Suramin45,46.
In summary, different inhibitors may bind to different regions of PLA2-like toxins of Bothrops sp snake venoms 
but may be classified into three different classes related to different mechanisms of inhibition: (1) Inhibitors that 
block the access to the hydrophobic channel for fatty acid molecules (inhibitors a and b, previous paragraph), 
impairing the natural movement between the monomers of the dimeric structure; (2) inhibitors that bind to func-
tional sites of the proteins and block MDoS and MDiS interaction with cell membrane (inhibitors c and d), and 
(3) inhibitors that can induce protein oligomerization, leading to the combination of the previous mechanisms 
(inhibitor e) (Fig. 6; Table 3).
conclusion
We have described functional and structural studies involving a toxin isolated from Bothrops moojeni venom, 
MjTX-II, and the inhibitor Varespladib. The results obtained by in vitro and in vivo experiments reveal that this 
synthetic compound is able to inhibit the myotoxic and cytotoxic effects of MjTX-II, a well characterized mem-
ber of the Lys49-PLA2-like myotoxins, widespread among many crotaline snake species. Given that the safety of 
Varespladib has been already confirmed in clinical trials, present results strengthen the importance of this com-
pound as a repurposed drug candidate to aid in the treatment of snakebite envenomings. The crystal structure 
and MD simulations described the interaction of Varespladib with a site similar to that of fatty acids binding and 
with the MDiS site, suggesting that the inhibition of MjTX-II by Varespladib is due to physical blockage of the 
interaction with allosteric activator molecules in the hydrophobic channel, and by restricting the movement of 
the MDiS of these toxins, preventing the alignment of its functional sites and, consequently, impairing its ability 
Figure 5. Interaction of Varespladib and myristic acid (FA14) with side chain of residues from Helix-I, 
hydrophobic channel and MDiS residues. (A) Overall crystal structure of MjTX-II/Varespladib (cyan), zoomed 
region of contacts of inhibitor to side chain of aminoacids from protein and the same region after 90° of 
rotation. (B) Overall of crystal structure of MjTX-II/FA14 (green), zoomed region from the interaction of fatty 
acid molecule with the protein and the same region after 90° of rotation.
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to disrupt the integrity of membranes. Furthermore, based on the crystallographic structure analyses, the distinc-
tion between activators and inhibitors is discussed, and the three classes of inhibition mechanisms for PLA2-like 
proteins are proposed.
Methods
toxin and varespladib. The isolation of MjTX-II from crude venom of B. moojeni was previously 
described50,56. Varespladib (compound LY315920) in free acid form was kindly provided by Ophirex. Inc. (origi-
nal source: ChemieTek, Indianapolis, Indiana, USA; 99.99% pure by NMR and HPLC).
In vivo myotoxicity. Myotoxic activity assays were carried out in groups of five CD-1 mice (18–20 g body 
weight), which had access to food and water ad libitum, as described previously62. One group of mice was injected in 
the gastrocnemius muscle with 50 µg of toxin dissolved in 100 µL of phosphate-buffered saline (PBS, pH 7.2; 0.12 M 
NaCl, 0.04 M sodium phosphate). A mixture of 50 µg of toxin and 400 mM Varespladib (in 4% dimethyl sulfoxide; 
DMSO) was preincubated for 15 min at room temperature, and subsequently injected in another group of mice 
under otherwise identical conditions. Control groups of four mice were injected with either 100 µL of PBS, or 100 µL 
of 4% DMSO in PBS, respectively. After 3 h, blood was collected from the tip of the tail into a heparinized capillary 
and centrifuged. Then, plasma creatine kinase (CK) activity, expressed in U/L, was determined using a UV kinetic 
assay (CK-NAC UV, Wiener Lab). Animal experiments were approved by ‘Comité Institucional para el Cuidado y 
Uso de los Animales (CICUA, permit #084-17), Universidad de Costa Rica. After the experiments, mice were sacri-
ficed by CO2 inhalation. For comparison of mean values from more than two groups, ANOVA was used followed by 
Tukey-Kramer tests, and differences were considered statistically significant when p < 0.05.
In vitro cytotoxicity on c2c12 myoblasts. Murine C2C12 skeletal muscle myoblast cells (CRL-1772; 
American Type Culture Collection) were used in cytotoxicity assays, as previously described16,48. The assays were 
performed using a stock solution of Varespladib dissolved at 10 mM in dimethyl sulfoxide (DMSO). This solution 
was diluted prior to each assay with the corresponding buffers to a final concentration of 400 µM, decreasing the 
DMSO concentration to 4%. Control tests performed preliminarily showed that this concentration of DMSO 
did not result in a cytotoxic effect in the assay system. The C2C12 cell cultures were maintained as undifferenti-
ated myoblasts at subconfluent levels in Dulbecco’s modified Eagle’s medium (DMEM, Sigma) supplemented 
with 10% fetal bovine serum (FBS), L-glutamine and penicillin/streptomycin. Cells (approximately 105/200 µL) 
were added to each well of a 96-well plate and incubated at 37 °C, with a 7% CO2 humidified atmosphere. When 
cultures reached 80–90% confluence, myoblasts were incubated with either toxin alone or toxin that had been 
pre-incubated with Varespladib (400 µM) for 15 min at room temperature. After 3 h of cell exposure at 37 °C, an 
aliquot of 60 µL of each supernatant was obtained to quantify the activity of lactate dehydrogenase (LDH) release 
from damaged cells, using a commercial assay (LDH-P UVAA - Wiener Lab). The LDH activity in supernatants 
of cells exposed to DMEM alone, or DMEM containing 0.1% Triton X-100, was considered as 0% and 100% 
Figure 6. Different forms of inhibition of Lys49 PLA2-like toxins by inhibitors described in literature. The 
monomer A is showed as light gray and the monomer B is represented as dark gray (A) Class 1 inhibitors 
(yellow), which prevent the binding of fatty acids (yellow sticks - activator) to hydrophobic channel (cyan) 
of toxin. (B) Class 2 inhibitors (blue) which bind to functional MDoS (green) and MDiS (red) and prevent 
the interaction of toxin to membrane (orange). (C) Class 3 inhibitors (magenta) which induce protein 
oligomerization.
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reference points, respectively. The assays were performed in triplicate cell cultures and the results are presented 
as mean ± SD. The statistical significance of differences between means of two groups was determined by the 
Student’s t-test, where values of p < 0.05 were considered significant.
Crystallization and X-ray data collection. Crystallization trials for MjTX-II/Varespladib complex were 
performed using the purified toxin concentrated up to 10 mg.mL−1 (diluted in 20 mM ammonium bicarbonate 
pH 8.0) and Varespladib (diluted in 100% DMSO) added to obtain the molar ratio of 1:10 respectively. Crystals 
of the MjTX-II/Varespladib complex were obtained by conventional hanging drop vapor-diffusion method63 at 
291 K from a drop mixture of 0.7 µL of protein, 0.3 µL Varespladib and 1 µL reservoir solution equilibrated against 
500 µL reservoir. The reservoir cocktail was composed by 30% v/w polyethylene glycol (PEG) 4000, 0.1 M TrisHCl 
pH 8.5 and 0.2 M lithium sulfate.
A dataset was obtained using a synchrotron radiation source (MX2 station, Laboratório Nacional de Luz Sincrotron 
(LNLS), Campinas, Brazil) and a PILATUS 2 M detector (Dectris) using a wavelength of 1.459 Å (at 100 K). The X-ray 
diffraction data were collected using crystal-to-detector distance of 100 mm, oscillation of 1° per frame resulting in 250 
frames. The processing was executed using the HKL2000 v.1.8.4 program package64 as described Table 1.
Structure determination and refinement. The crystal structure of MjTX-II/Varespladib was solved by 
the molecular replacement method using the program PHASER65 from PHENIX package v.1.1266. The coordi-
nates of the monomer A from MjTX-II (PDB access code 4KF3) was used as search model. The manual modeling 
and refinement process of the protein, insertion of Varespladib, DMSO and solvent molecules were performed 
using program Coot v.0.8.967. Structural automated refinement and the general quality check of models were 
performed using PHENIX package v.1.1266 and MolProbity program (http://molprobity.biochem.duke.edu/)68.
Structural comparative analysis. For the structural comparisons, the structures of the MjTX-II/
Varespladib presented here and structures presented in Table 3 were used. Molecular comparisons of structures 
were performed using Coot v.0.8.967 and PyMOL v.1.8.669 programs. All structural figures were generated using 
PyMOL v.1.8.669 program.
Molecular dynamics (MD) simulations. MD simulations of MjTX-II in complex with Varespladib were 
carried out using GROMACS (Groningen Machine for Chemical Simulation) v.5.0.570 under the CHARMM36 
force field71. All the initial input parameters and Varespladib topology were generated by CHARMM-GUI web-
server72 and the protonation of the residues was set to pH 7.0 determined by PROPKA3 server73. The complex 
was placed in a cubic box with 5 Å from the farthest atom, solvated with TIP3P water molecules and equilibrated 
with 100 mM of NaCl. Further, the system was minimized until reaching an energy below 100 kJ/mol/nm using 
the Steepest Descent algorithm. A 1-ns NVT ensemble was performed generating the velocities randomly accord-
ing to Maxwell-Boltzmann distribution at temperature of 300 K using the V-rescale thermostat74 followed of a 
1-ns NPT ensemble with Berendsen barostat75 at 1 bar. Both steps were performed restraining the backbone and 
hydrogen atoms of the protein and Varespladib, respectively. A following step of an unrestrained 100 ns NPT step 
was performed using the Nose-Hoover thermostat76,77 and Parrinello-Rahman barostat78. Short-range cutoffs for 
electrostatic and Van der Waals interactions were set to 12 Å with a force-switch function from 10 to 12 Å and 
hydrogen bonds were constrained using LINCS algorithm79.
The binding energy (ΔG) of the MjTX-II/Varespladib complex was predicted using the MM-PBSA method 
implemented in g_mmpbsa software80, collecting the frames every 500 ps for the last 10 ns of MD simulation. 
As MjTX-II has many charged residues, the solute dielectric constant (εsolute) was set to 8. In order to compare 
the ΔG value of Varespladib with other molecules bound to the same toxin, inhibitors from classes 1, 2 and 3 
(Table 3) were selected: (i) Rosmarinic Acid (PDB ID: 6MQD)50, and (ii) Suramin (PDB ID: 4YV5)45, then ΔG 
values were calculated using the same protocol as for Varespladib.
The prevalence of contacts of the MjTX-II residues and Varespladib molecules were calculated selecting the 
residues that interacted with the ligand below a cutoff of 4.5 Å from the crystallographic structure. Further, these 
residues were analyzed according to the minimal distance to Varespladib molecules for each frame from MD 
simulations considering an interaction only when below the cutoff, then these interactions were converted to 
percentage and classified as weak (<50%), moderate (<80% and >50%) or strong (>80%). Root-Mean-Square 
Deviation (RMSD), Root-Mean-Square-Fluctuations (RMSF) and Solvent-Accessibly Surface Area (SASA) cal-
culations were performed using built-in tools provided by GROMACS.
ethical statement. Experiments in mice were approved by the Institutional Committee for the Care and 
Use of Laboratory Animals (CICUA), Universidad de Costa Rica (permit #084-17). Animal procedures were 
in accordance with the guidelines for animal care prepared by the Committee on Care and Use of Laboratory 
Animal Resources, National Research Council, USA.
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